<DOC>
	<DOCNO>NCT02620527</DOCNO>
	<brief_summary>Foundation Medicine Inc. ( FMI ) interest study concordance genomic alteration primary and/or metastatic surgical biopsy , circulate tumor DNA ( ctDNA ) within different solid tumor type develop assay order .</brief_summary>
	<brief_title>Concordance Between ctDNA Assay FoundationOne</brief_title>
	<detailed_description>The purpose study ass whether new ctDNA assay develop Foundation Medicine able detect genomic alteration peripheral blood consistent genomic alteration detect patient 's matched primary and/or metastatic tumor biopsy sample analyze FoundationOne® test . Study sit provide match solid tumor peripheral blood sample cancer patient FMI purpose test concordance FMI ctDNA assay FoundationOne® test . Participation study part broader 2000 patient study determine tumor type readily measure via ctDNA profiling , learn similarity alteration find patient 's tumor biopsy ctDNA blood .</detailed_description>
	<criteria>Patients solid tumor biopsy isolate analysis FoundationOne standard clinical care Tumor specimens cancer representative diagnosis find submit tissue Tumor specimens insufficient DNA ( &lt; 50 ng ) provide run FoundationOne test . Tumor specimens ≤20 % tumor nucleus ( specimen ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Circulating Tumor DNA</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Genomic Testing</keyword>
	<keyword>FoundationOne</keyword>
	<keyword>Cell Free DNA</keyword>
	<keyword>ctDNA</keyword>
	<keyword>cfDNA</keyword>
</DOC>